Zyprexa documents ppt 6.

1
Zyprexa documents ppt 6.

• This powerpoint has a selection of pages from
  documents to do with managing Adverse Drug Event
  issues.

2
ZY100737693 Letter re 10 metabolic ADEs
Sep2002
3
ZY100413599, ZY100413600, ZY100413601 tables
Jan 2003 on spont ADEs re diabetes, pancreatitis
to June 2002
4
ZY200399435 email re Prof Newcomer and
Csernansky prestn in UK re diabetes and atyps
Aug 2002they request the literature I reference
5
ZY200399435 email re Prof Newcomer and
Csernansky prestn in UK re diabetes and atyps
Aug 2002
6
ZY200399435 email re Prof Newcomer and
Csernansky prestn in UK re diabetes and atyps
Aug 2002
7
ZY200399435 email re Prof Newcomer and
Csernansky prestn in UK re diabetes and atyps
Aug 2002if I were with Janssen, Id be throwing
some cash at this chap
8
ZY201300048 email re pharmacoepidemiol study
showing Olz and Clozapine had greater odds ratio
for being on antidiabetes meds Oct2002
9
ZY100570361 copy of letter of a medical
director re Zyp weight gain faxed to E-L Mar 2003
10
ZY200570518 Tough questions debated at Lilly
Apr2003 mtg
11
ZY100014182 APA 2003 reviewdealing with
metabolic ADEs
12
ZY100014182 APA 2003 reviewdealing with
atypicals v typicals debate
13
ZY100386523 regulatory activity timeline from
1985 to FDA decision 15 Sep 2003
14
ZY201588819 internal Lilly lit rv on
comparative metab ADEs of atypicals undated but
latest ref used 2003.
15
ZY201588819 internal Lilly lit rv on
comparative metab ADEs of atypicals undated but
latest ref used 2003.
16
ZY201588819 internal Lilly lit rv on
comparative metab ADEs of atypicals undated but
latest ref used 2003.anonymous Lilly reviewer
concludes Risp and Quet are more likely to have
metab ADEs than current warnings, but also that
Olz sits with Cloz as most likely agents to give
metabolic ADEs
17
ZY201588819 internal Lilly lit rv on
comparative metab ADEs of atypicals undated but
latest ref used 2003.anonymous Lilly reviewer
concludes Risp and Quet are more likely to have
metab ADEs than current warnings, but also that
Olz sits with Cloz as most likely agents to give
metabolic ADEs
18
ZY201588969 letter to ADA protesting
differential warnings on atypicals Jan 2004
19
ZY201588416 email re influence plan
diabetes/wght gain Feb 2004
20
ZY201239720 Competitive info briefing from
interviews with Prof Newcomer other
advisorsFeb2004
21
ZYZY201239720 Competitive info briefing from
interviews with Prof Newcomer other
advisorsFeb 2004
22
ZYZY201239720 Competitive info briefing from
interviews with Prof Newcomer other
advisorsFeb 2004
23
ZY201239728 Competitive info briefing re APA
subcommitteMar2004...APA refused to sign on to
ADA work until it saw a draft. APA felt that if
the ADA pronouncements were politically
explosive, it would upset the APA
sponsors...APA American Psychiatric
AssociationADA American Diabetes Association
24
ZY201239728 Competitive info briefing re APA
subcommitteMar2004
25
ZY201862763 email re Stahl, Meyer CME on
atypicals and diabetes Olanzapine big offender
June 2004
26
ZY201862763 email re Stahl, Meyer CME on
atypicals and diabetes Olanzapine big offender
June 2004
27
ZY201862763 email re Stahl, Meyer CME on
atypicals and diabetes Olanzapine big offender
June 2004
28
ZY201238586 Issue management wght
gain/diabetesmid 2003
29
ZY201238586 Issue management wght
gain/diabetes mid 2003
30
ZY201238586 Issue management wght
gain/diabetes mid 2003
31
ZY201238586 Issue management wght
gain/diabetes mid 2003
32
ZY201238586 Issue management wght
gain/diabetes mid 2003
33
ZY200583203 Issues management and competitive
strategyJuly2003
34
ZY200583203 Issues management and competitive
strategyJuly2003
35
ZY200583203 Issues management and competitive
strategyJuly2003
36
ZY200583203 Issues management and competitive
strategyJuly2003
37
ZY200192865 Integrating wght gain into the brand
promise
38
ZY200523684 Weight Task Force Jan 2004
39
ZY200523684 Weight Task Force Jan 2004
40
ZY200523684 Weight Task Force Jan 2004
41
ZY200523684 Weight Task Force Jan 2004
42
ZY200523684 Weight Task Force Jan 2004
43
ZY200523684 Weight Task Force Jan 2004
44
ZY200523684 Weight Task Force Jan 2004
45
ZY200523684 Weight Task Force Jan 2004
46
ZY200523684 Weight Task Force Jan 2004
47
ZY200523684 Weight Task Force Jan 2004
48
ZY200523684 Weight Task Force Jan 2004
49
ZY200506745 Managing wght gain diabetes
concerns CSF marketing Dec 2003
50
ZY200506745 Managing wght gain diabetes
concerns CSF marketing Dec 2003
51
ZY200662252 powerpt pres on response to ADA
consensus statement on atypicals diabetesearly
2004
52
ZY200662252 powerpt pres on response to ADA
consensus statement on atypicals diabetesearly
2004
53
ZY200662252 powerpt pres on response to ADA
consensus statement on atypicals diabetesearly
2004
54
ZY200662252 powerpt pres on response to ADA
consensus statement on atypicals diabetesearly
2004
55
ZY200662252 powerpt pres on response to ADA
consensus statement on atypicals diabetesearly
2004
56
ZY200662252 powerpt pres on response to ADA
consensus statement on atypicals diabetesearly
2004
57
ZY200521530 notes re handling ADA type
events.Feb 2004
58
ZY200521530 notes re handling ADA type
events.Feb 2004
59
ZY200521530 notes re handling ADA type
events.Feb 2004
60
ZY200521530 notes re handling ADA type
events.Feb 2004
61
ZY200581528 email our position (no
differential between atypicals on diabetes) is
making us look foolishMar 2004
62
ZY200598805 emails re literature saying
antipsychotics of equal efficacy Jan 2004
63
ZY200598805 emails re literature saying
antipsychotics of equal efficacy Jan 2004
64
ZY200598805 emails re literature saying
antipsychotics of equal efficacy Jan 2004
65
ZY201607921 marketplace strategy managing wgt
gain Jan 2005
66
ZY201607921 marketplace strategy managing wgt
gain Jan 2005
67
ZY201607921 marketplace strategy managing wgt
gain Jan 2005
68
ZY201607921 marketplace strategy managing wgt
gain Jan 2005
69
ZY201607921 marketplace strategy managing wgt
gain Jan 2005
70
ZY201607921 marketplace strategy managing wgt
gain Jan 2005